Compare Cigna Corp (CI) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cigna Corp vs Summit Therapeutics Inc — how do they compare? Cigna Corp trades at $278.01 (market cap $73.56B), while Summit Therapeutics Inc trades at $15.01 (market cap $12.06B). The key difference: Cigna Corp is far larger — about 6.1× Summit Therapeutics Inc's market cap, and Cigna Corp pays a 2.24% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| CI | SMMT | |
|---|---|---|
Market Cap | $73.56B | $12.06B |
Sector | Health | Health |
52-Week High | $311.00 | $26.98 |
52-Week Low | $244.41 | $12.55 |
Enterprise Value | $98.27B | $11.39B |
Dividend Yield | 2.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cigna (CI) trades at $275.4, down 1.08% today, with technical indicators signaling a bearish short-term trend. The stock shows strong fundamentals, including a low P/E of 11.51 and consistent earnings beats, with Q2 2026 EPS of $7.78 exceeding expectations. Recent news highlights raised 2026 EPS guidance to at least $30.45, driven by growth in health services and insurance segments.
The outlook is positive, supported by analyst consensus with a $338.90 price target and 73.68% buy ratings. Key risks include competitive pressures and regulatory changes in healthcare. The valuation gap presents an opportunity, but investors should monitor medical cost trends and execution of growth targets.
Summit Therapeutics (SMMT) trades at $15.23, up 2.42% today, with a bullish technical signal and strong analyst consensus. The stock shows mixed earnings performance but benefits from positive news on ivonescimab's regulatory progress and clinical expansions. Despite negative profitability metrics, investor sentiment is buoyed by a high price target of $38.00 and recent partnership announcements in cancer drug development.
Outlook hinges on FDA approval for ivonescimab by November 2026, offering significant upside if successful. Risks include cash burn, ongoing losses, and fiduciary investigations. The stock presents a high-risk, high-reward opportunity for speculative investors betting on clinical successes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cigna Corp
Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM services were greatly expanded by its 2018 merger with Express Scripts and are mostly sold to health insurance plans and employers. Its largest PBM contract is the Department of Defense. In health insurance and other benefits, Cigna mostly serves employers through self-funding arrangements, but it also operates in government programs, such as Medicare Advantage. The company operates mostly in the U.S. with 15 million medical members covered as of the end of 2020, but its services extend internationally, covering another 2 million people.
Read more on CI →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
